Baxalta Inc (BXLT) : Whitebox Advisors added new position in Baxalta Inc during the most recent quarter end. The investment management firm now holds 500,000 shares of Baxalta Inc which is valued at $20,585,000 , the company said in a statement filed on May 3, 2016 with the SEC.Baxalta Inc makes up approximately 3.12% of Whitebox Advisors’s portfolio.
Other Hedge Funds, Including , Parkside Financial Bank Trust boosted its stake in BXLT in the latest quarter, The investment management firm added 94 additional shares and now holds a total of 775 shares of Baxalta Inc which is valued at $31,907. Baxalta Inc makes up approx 0.02% of Parkside Financial Bank Trust’s portfolio. Evergreen Capital Management sold out all of its stake in BXLT during the most recent quarter. The investment firm sold 39,544 shares of BXLT which is valued $1,628,026.United Bank reduced its stake in BXLT by selling 46,903 shares or 73.28% in the most recent quarter. The Hedge Fund company now holds 17,102 shares of BXLT which is valued at $717,429. Baxalta Inc makes up approx 0.32% of United Bank’s portfolio.Integrated Wealth Management reduced its stake in BXLT by selling 77 shares or 1.2% in the most recent quarter. The Hedge Fund company now holds 6,346 shares of BXLT which is valued at $262,597. Baxalta Inc makes up approx 0.11% of Integrated Wealth Management’s portfolio.Trillium Asset Management reduced its stake in BXLT by selling 30,594 shares or 76.67% in the most recent quarter. The Hedge Fund company now holds 9,312 shares of BXLT which is valued at $385,331. Baxalta Inc makes up approx 0.03% of Trillium Asset Management’s portfolio.
Baxalta Inc opened for trading at $42.48 and hit $43.06 on the upside on Tuesday, eventually ending the session at $42.93, with a gain of 1.37% or 0.58 points. The heightened volatility saw the trading volume jump to 98,51,416 shares. Company has a market cap of $29,344 M.
On the company’s financial health, Baxalta Inc reported $0.47 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $0.46. The company had revenue of $1548.00 million for the quarter, compared to analysts expectations of $1474.42 million. The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.40 EPS.
Baxalta Incorporated is a biopharmaceutical company. The Company develops manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute medical conditions. The Company also focuses on disease areas including oncology as well as technology platforms including gene therapy and biosimilars. The Company has a portfolio of various therapies that address unmet medical needs across various disease areas including hemophilia immunology and oncology. The Company’s products include ADVATE RECOMBINATE HEMOFIL M Immunate Immunine PROTHROMPLEX TOTAL RIXUBIS FACTOR VII NF BEBULIN FEIBA OBIZUR GAMMAGARD LIQUID GAMMAGARD S/D Subcuvia HYQVIA FLEXBUMIN BUMINATE ARALAST NP GLASSIA NP CEPROTIN and ANTITHROMBIN III IMMUNO.